LipoScience(LPDX)- NASDAQ
LPDX is defunct.
  • Nov. 12, 2014, 10:02 AM
    • LipoScience (LPDX +0.2%) Q3 results: Revenues: $8.6M (-32.3%); COGS: $2.3M (-11.5%); Operating Expenses: $10.1M (-29.4%); Operating Loss: ($3.8M) (+9.5%); Net Loss: ($4.3M) (+6.5%); Loss Per Share: ($0.28) (+9.7%); Quick Assets: $40M (-20.0%); CF Ops: ($5.4M) (+40%).
    • No guidance given.
    | Nov. 12, 2014, 10:02 AM
  • Nov. 12, 2014, 7:32 AM
    • LipoScience (NASDAQ:LPDX): Q3 EPS of -$0.28 misses by $0.02.
    • Revenue of $8.6M (-32.3% Y/Y) misses by $0.2M.
    | Nov. 12, 2014, 7:32 AM
  • Sep. 25, 2014, 12:45 PM
    | Sep. 25, 2014, 12:45 PM
  • Sep. 25, 2014, 9:17 AM
    | Sep. 25, 2014, 9:17 AM
  • Sep. 25, 2014, 7:40 AM
    • LabCorp (NYSE:LH) acquires LipoScience (NASDAQ:LPDX) for $5.25 per share in cash (transaction value: $85.3M). The transaction will be accretive to earnings in year one and accretive to cost of capital by year three.
    • LipoScience develops diagnostic tests based on nuclear magnetic resonance (NMR). Its first product, the NMR LipoProfile test, directly quantifies LDL particle number (LDL-P) and provides physicians and patients with actionable information to personalize management of heart disease.
    • LPDX is up 64% premarket on high volume.
    | Sep. 25, 2014, 7:40 AM
  • Aug. 12, 2014, 5:47 PM
    • LipoScience (LPDX -0.3%) Q2 results: Revenues: $9.0M (-32.1%); Operating Expenses: $10.2M (-19.7%); Net Loss: ($4.1M) (-66.0%); Loss Per Share: ($0.27) (-58.8%); Quick Assets: $42.8M (-13.7%); Cash Burn (1H): ($3.6M) (+47.9%).
    • Q3 Guidance: revenue: $8.5M - 9.0M; volume: 320K - 340K; gross margin: low- to mid-70% range; operating expenses: $10.2M - 10.5M; cash usage: $5M.
    | Aug. 12, 2014, 5:47 PM
  • Aug. 12, 2014, 4:19 PM
    • LipoScience (NASDAQ:LPDX): Q2 EPS of -$0.27 misses by $0.03.
    • Revenue of $9M (-32.4% Y/Y) beats by $0.05M.
    | Aug. 12, 2014, 4:19 PM
  • May 12, 2014, 6:03 PM
    • LipoScience (LPDX): Q1 EPS of -$0.13 beats by $0.06.
    • Revenue of $12M (-11.8% Y/Y) misses by $0.03M.
    | May 12, 2014, 6:03 PM
  • May 5, 2014, 7:29 AM
    • In an effort to manage its costs and streamline its operations, nano cap LipoScience (LPDX) terminates its contract with Health Diagnostic Laboratory and cuts 22 jobs.
    • Consensus revenue estimates for Q1 and 2014 are $12M and $48M, respectively.
    • 23 mutual funds have positions, down from 41 a year earlier.
    | May 5, 2014, 7:29 AM
  • Mar. 28, 2014, 12:45 PM
    | Mar. 28, 2014, 12:45 PM
  • Mar. 28, 2014, 9:12 AM
    | Mar. 28, 2014, 9:12 AM | 3 Comments
  • Mar. 10, 2014, 5:13 PM
    • LipoScience (LPDX): Q4 EPS of -$0.17 beats by $0.07.
    • Revenue of $12.7M (-6.3% Y/Y) in-line.
    | Mar. 10, 2014, 5:13 PM
  • Sep. 6, 2013, 11:29 AM
    • LipoScience (LPDX +2%) appoints William Cromwell, M.D., as the company's chief medical officer.
    • He joins LPDX for a second time, having previously served in the same position from 1999 - 2005.
    • Cromwell replaces Robert M Honigberg, who announced last month that he was resigning effective September 17 for family-related reasons.
    | Sep. 6, 2013, 11:29 AM
  • Aug. 26, 2013, 7:35 PM
    • LipoScience (LPDX) says its Chief Medical Officer, Robert M Honigberg, is resigning effective September 17 for family-related reasons.
    | Aug. 26, 2013, 7:35 PM
  • Aug. 6, 2013, 6:51 AM
    • LipoScience (LPDX): Q2 EPS of -$0.17 beats by $0.01.
    • Revenue of $13.3M misses by $0.25M. (PR)
    | Aug. 6, 2013, 6:51 AM
  • Aug. 2, 2013, 3:08 PM
    • LipoScience (LPDX -10.7%) plummets as CEO Richard Brajer steps down "to pursue other interests."
    • Robert Greczyn is named interim CEO.
    • The company says Q2 revenues will likely come in at $13.3M, towards the low end of guidance. Consensus is $13.6M
    • For the full year, the company cuts its revenue guidance to $52-54M, down from $54-56M, and below Street estimates of $55.37M. (PR)
    | Aug. 2, 2013, 3:08 PM